These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 33499913

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
    Smolen JS, Sebba A, Ruderman EM, Schulze-Koops H, Sapin C, Gellett AM, Sprabery AT, Li L, de la Torre I, Gallo G, Liu-Leage S, Pillai S, Reis P, Nash P.
    Rheumatol Ther; 2020 Dec; 7(4):1021-1035. PubMed ID: 33200394
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).
    Orbai AM, Gratacós J, Turkiewicz A, Hall S, Dokoupilova E, Combe B, Nash P, Gallo G, Bertram CC, Gellett AM, Sprabery AT, Birt J, Macpherson L, Geneus VJ, Constantin A.
    Rheumatol Ther; 2021 Mar; 8(1):199-217. PubMed ID: 33278016
    [Abstract] [Full Text] [Related]

  • 5. Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
    Armstrong AW, Jaleel T, Merola JF, Gottlieb AB, Khattri S, Helt CC, Malatestinic WN, Ross SE, Ngantcha ME, de Vlam K.
    Dermatol Ther (Heidelb); 2024 Jun; 14(6):1615-1631. PubMed ID: 38814433
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, Shuler CL, Carlier H, Benichou O, Mease PJ.
    J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
    [Abstract] [Full Text] [Related]

  • 7. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
    Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacós J, Goupille P, Liu Leage S, Pillai S, Nash P.
    Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
    [Abstract] [Full Text] [Related]

  • 8. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.
    Deodhar A, Gladman D, Bolce R, Sandoval D, Park SY, Leage SL, Nash P, Poddubnyy D.
    Ther Adv Musculoskelet Dis; 2023 Oct; 15():1759720X231189005. PubMed ID: 37645684
    [Abstract] [Full Text] [Related]

  • 9. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
    Kirkham B, Sesin C, Gellett AM, Sprabery AT, Lin CY, Turkiewicz A.
    Rheumatology (Oxford); 2021 Sep 01; 60(9):4367-4372. PubMed ID: 33479721
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.
    Clin Ther; 2003 Jun 01; 25(6):1700-21. PubMed ID: 12860493
    [Abstract] [Full Text] [Related]

  • 15. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
    Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M, SPIRIT-P2 Study Group.
    Lancet; 2017 Jun 10; 389(10086):2317-2327. PubMed ID: 28551073
    [Abstract] [Full Text] [Related]

  • 16. Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis.
    Orbai AM, Gladman DD, Goto H, Birt JA, Gellett AM, Lin CY, Kvien TK.
    Clin Exp Rheumatol; 2021 Jun 10; 39(2):329-336. PubMed ID: 32573426
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
    Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, Lee C, Kerr L, Nash P.
    Rheumatology (Oxford); 2018 Nov 01; 57(11):2001-2011. PubMed ID: 30053162
    [Abstract] [Full Text] [Related]

  • 18. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
    Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.
    Rheumatology (Oxford); 2018 Oct 01; 57(10):1777-1788. PubMed ID: 29945203
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.